A new antibody-drug conjugate has shown promising results in a clinical trial for aggressive triple-negative breast cancer. The targeted therapy, which combines an antibody with chemotherapy, significantly extended progression-free survival and overall survival compared to traditional chemotherapy. It also led to higher rates of tumor shrinkage and longer-lasting responses, offering a potentially improved first-line treatment option for patients with limited choices. AI
RANK_REASON Clinical trial results for a new drug treatment. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
